GC	Gastric cancer
CLDN 18.2	Claudin 18 isoform 2
AGC	Advanced GC
GC	Gastric cancer
GEJ	Gastroesophageal junction
G/GEJ	Gastric/ Gastroesophageal junction
HER2	Epidermal growth factor receptor 2
CLDN	Claudin
OS	Overall survival
LAST 1/2	Large tumor suppressor kinase 1/2
YAP1	Yes-associated protein 1
ICI	Immune checkpoint inhibitor
mAb	Monoclonal antibody
PD-1	Programmed cell death-1
GS	Genomically stable
IHC	Immunohistochemistry
PD-L1	Programmed cell death-ligand 1
dMMR	Deficient mismatch repair
MSI	Microsatellite instability
FGFR2	Fibroblast growth factor receptor 2
EBV	Epstein–Barr virus
CPS	Combined positive score
BsAbs	Bispecific antibodies
CAR	Chimeric antigen receptor
ADC	Antibody–drug conjugates
IgG1	Immunoglobulin G1
ADCC	Antibody-dependent cellular cytotoxicity
CDC	Complement-dependent cytotoxicity
ADCP	Antibody-dependent cellular phagocytosis
DLT	Dose-limiting toxicity
AE	Adverse event
TRAEs	Treatment-related AEs
PK	Pharmacokinetics
PD	Pharmacodynamics
ORR	Objective response rate
DCR	Disease control rate
PFS	Progression-free survival
DoR	Duration of response
mFOLFOX	Modified FOLFOX (5-FU + Leucovorin + Oxaliplatin)
EOX	Epirubicin + Oxaliplatin + Capecitabine
HR	Hazard ratio
CI	Confidence interval
CAPOX	Capecitabine + Oxaliplatin
CR	Complete response
PR	Partial Response
SD	Stable disease
FcγRIIIa	CD16a
mRNA	Messenger ribonucleic acid
RP2D	Recommended phase II dose
MTD	Maximum tolerated dose
VHH	Variable domain of Heavy chain of Heavy chain
CDX	Cell-derived xenograft
PDX	Patient-derived xenograft
NK	Natural killer
DCs	Dendritic cells
BiTE	Bispecific T-cell engager
AT-BOIN	Accelerated titration-Bayesian optimal interval
TAA	Tumor-associated antigen
MMAE	Monomethyl auristatin E
Q3W	Once-every-3-weeks
CRS	Cytokine release syndrome
DNA	Deoxyribonucleic acid
NKD2G	Natural killer group 2, member D
TAC	T-cell antigen coupler
mRNA	Messenger RNA
RNase	Ribonuclease
LNPs	Lipid nanoparticles